Type 2 myotonic dystrophy can be predicted by the combination of type 2 muscle fiber central nucleation and scattered atrophy

Journal of Neuropathology and Experimental Neurology

Volumn 67, Issue 4, 2008, Pages 319-325

  Bassez, Guillaume ^a,b,c,d   Chapoy, Elisabeth ^a,b,c   Bastuji Garin, Sylvie ^d   Radvanyi Hoffman, Hélène ^e   Authier, Francois Jérôme ^a,b,c   Pellissier, Jean François ^f   Eymard, Bruno ^g   Gherardi, Romain K ^a,b,c  

^a INSERM   (France)

^b FACULTÉ DE MÉDECINE   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e HÔPITAL AMBROISE PARÉ   (France)

^f TIMONE HOSPITAL   (France)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

In situ hybridization; Muscle biopsy; Myotonic dystrophy; Tetranucleotide repeat expansion; Type 2 myotonic dystrophy

Indexed keywords

RIBONUCLEOPROTEIN;

ADULT; ARTICLE; CELL STRUCTURE; CENTRAL NUCLEATION; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MUSCLE ATROPHY; MUSCLE BIOPSY; MUSCLE CELL; MYOPATHY; MYOTONIC DYSTROPHY; MYOTONIC DYSTROPHY TYPE 2; PRIORITY JOURNAL; SCATTERED ATROPHY; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE;

AGED; ANALYSIS OF VARIANCE; ATROPHY; CELL NUCLEUS; DNA REPEAT EXPANSION; FEMALE; HUMANS; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; MUSCLE FIBERS, FAST-TWITCH; MYOSIN HEAVY CHAINS; MYOTONIC DISORDERS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RNA-BINDING PROTEINS;

EID: 41949105232     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/NEN.0b013e31816b4acc     Document Type: Article

References (21)

1. Ashizawa T. The International Myotonic Dystrophy Consortium (IDMC): New nomenclature and DNA testing guidelines for myotonic dystrophy type 1 (DM1). Neurology 2000;54:1218-21
2. Liquori C, Ricker K, Moseley ML, et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 2001;293:864-67
3. Harper PS. Myotonic Dystrophy. 3rd ed. London, UK: Saunders, 2001
4. Meola G, Moxley RT. Myotonic dystrophy type 2 and related myotonic disorders. J Neurol 2004;251:1173-82
5. Moxley RT 3rd, Meola G, Udd B, et al. Report of the 84th ENMC workshop: PROMM (proximal myotonic myopathy) and other myotonic dystrophy-like syndromes: 2nd workshop. 13-15th October, 2000, Loosdrecht, The Netherlands. Neuromuscul Disord 2002;12:306-17
6. Schoser BG, Schneider-Gold C, Kress W, et al. Muscle pathology in 57 patients with myotonic dystrophy type 2. Muscle Nerve 2004;29:275-81
7. Sallinen R, Vihola A, Bachinski LL, et al. New methods for molecular diagnosis and demonstration of the (CCTG)n mutation in myotonic dystrophy type 2 (DM2). Neuromuscul Disord 2004;14:274-83
8. Day JW, Ricker K, Jacobsen JF, et al. Myotonic dystrophy type 2: Molecular, diagnostic and clinical spectrum. Neurology 2003;60:657-64
9. Udd B, Meola G, Krahe R, et al. 140th ENMC International Workshop: Myotonic dystrophy DM2/PROMM and other myotonic dystrophies with guidelines on management. Neuromuscul Disord 2006;16:403-13
10. Ricker K, Koch MC, Lehmann-Horn F, et al. Proximal myotonic myopathy: A new dominant disorder with myotonia, muscle weakness, and cataracts. Neurology 1994;44:1448-52
11. Day JW, Ranum LP. RNA pathogenesis of the myotonic dystrophies. Neuromuscul Disord 2005;15:5-16
12. Bassez G, Attarian S, Laforêt P, et al. Myopathie proximale avec myotonie (PROMM): Étude clinique et histologique. Rev Neurol 2001;157:209-18
13. Vihola A, Bassez G, Meola G, et al. Histopathological differences of myotonic dystrophy type 1 (DM1) and PROMM/DM2. Neurology 2003;60:1854-57
14. Mankodi A, Urbinati CR, Yuan QP, et al. Muscleblind localizes to nuclear foci of aberrant RNA in myotonic dystrophy types 1 and 2. Hum Mol Genet 2001;10:2165-70
15. Lueck JD, Mankodi A, Swanson MS, et al. Muscle chloride channel dysfunction in two mouse models of myotonic dystrophy. J Gen Physiol 2007;129:79-94
16. Cardani R, Mancinelli E, Sansone V, et al. Biomolecular identification of (CCTG)n mutation in myotonic dystrophy type 2 (DM2) by FISH on muscle biopsy. Eur J Histochem 2004;48:437-42
17. Sackett DL, Haynes RB. The architecture of diagnostic research. BMJ 2002;324:539-41
18. Warner JP, Barron LH, Goudie D, et al. A general method for the detection of large CAG repeat expansions by fluorescent PCR. J Med Genet 1996;33:1022-26
19. Margolis JM, Schoser BG, Moseley ML, et al. DM2 intronic expansions: Evidence for CCUG accumulation without flanking sequence or effects on ZNF9 mRNA processing or protein expression. Hum Mol Genet 2006;15:1808-15
20. Rudnicki DD, Holmes SE, Lin MW, et al. Huntington's disease-like 2 is associated with CUG repeat-containing RNA foci. Ann Neurol 2007;61:272-82
21. Mankodi A, Teng-Umnuay P, Krym M, et al. Ribonuclear inclusions in skeletal muscle in myotonic dystrophy types 1 and 2. Ann Neurol 2003;54:760-68